Fig. 1: Mutation overview and analysis for SDFM, TCGA, and QCMG cohort. | npj Precision Oncology

Fig. 1: Mutation overview and analysis for SDFM, TCGA, and QCMG cohort.

From: Molecular characterization and prognostic implications of KRAS mutations in pancreatic cancer patients: insights from multi-cohort analysis

Fig. 1

The mutation landscape and co-mutation patterns of the top 20 genes in pancreatic cancer patients were analyzed across three distinct cohorts: 113 patients from the SDFM cohort (A), 183 patients from the TCGA cohort (B), and 383 patients from the QCMG cohort (C); Additionally, in all three cohorts, PDAC patients with mutations in KRAS, TP53, and CDKN2A exhibited significantly higher TMB values compared to those with wild-type alleles (P < 0.01), whereas no significant correlation was observed for SMAD4 mutations (D–F).

Back to article page